A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples